US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MetaVia Inc

1.53

+0.07004.79%

Post-market: 1.49-0.0436-2.85%16:29 EDT

Volume:37.59K

Turnover:56.35K

Market Cap:10.08M

PE:-0.41

High:1.53

Open:1.44

Low:1.44

Close:1.46

52wk High:19.03

52wk Low:0.9661

Shares:6.59M

Float Shares:4.81M

Volume Ratio:0.62

T/O Rate:0.78%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.7193

EPS(LYR):-7.3500

ROE:-175.68%

ROA:-58.82%

PB:1.48

PE(LYR):-0.21

Loading ...

Overview Company News Filings

MetaVia says Phase 1 trial shows DA-1726 cuts mean body weight up to 9.1% at 48 mg dose

Metavia Presents Higher-Dose Phase 1 Results for Da-1726 at Easl Congress 2026, Supporting Potential in Obesity and Mash

THOMSON REUTERS

Top Premarket Gainers

MT Newswires Live

Why MetaVia Stock Is Falling On Thursday?

MetaVia cites preclinical study showing vanoglipel reduces liver fibrosis in MASH

Sector Update: Healthcare Stocks Rise Tuesday Afternoon

MT Newswires Live

Top Premarket Gainers

MT Newswires Live

MetaVia Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

MetaVia presents Phase 1 higher-dose DA-1726 obesity data at ADA 2026 sessions

MetaVia Inc reports results for the quarter ended March 31 - Earnings Summary

MetaVia Q1 EPS $(0.79) Misses $(0.74) Estimate

Benzinga Earnings

MetaVia publishes investor presentation on obesity, MASH drug pipeline

MetaVia Q1 net loss widens 4.1% to $3.82 million

Metavia Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS

Press Release: MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update

MetaVia highlights higher-dose Phase 1 DA-1726 data in EASL late-breaking poster

MetaVia Inc expected to post a loss of 74 cents a share - Earnings Preview

MetaVia announces annual shareholder meeting webcast

MetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726

MetaVia doses first patient in higher-dose Phase 1 trial of obesity drug DA-1726

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/MTVA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MTVA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":1.53,"timestamp":1787601600000,"preClose":1.46,"halted":0,"volume":37587,"hourTrading":{"tag":"盘后","latestPrice":1.4864,"preClose":1.53,"latestTime":"16:29 EDT","volume":1352,"amount":2065.4800088,"timestamp":1787603388698,"change":-0.0436,"changeRate":-0.028497,"amplitude":0.035033},"delay":0,"changeRate":0.0479452054794521,"floatShares":4805200,"shares":6588099,"eps":-3.71934,"marketStatus":"Post-Mkt","change":0.07,"latestTime":"08-24 17:11:38 EDT","open":1.44,"high":1.53,"low":1.44,"amount":56354,"amplitude":0.061644,"askPrice":1.55,"askSize":28,"bidPrice":1.44,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.71934,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":1.46,"preHourTrading":{"tag":"盘前","latestPrice":1.5024,"preClose":1.46,"latestTime":"08:55 EDT","volume":4121,"amount":6100.778264099999,"timestamp":1787576130509,"change":0.0424,"changeRate":0.029041,"amplitude":0.078904},"postHourTrading":{"tag":"盘后","latestPrice":1.4864,"preClose":1.53,"latestTime":"16:29 EDT","volume":1352,"amount":2065.4800088,"timestamp":1787603388698,"change":-0.0436,"changeRate":-0.028497,"amplitude":0.035033},"volumeRatio":0.616118},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","floatShares":4805200,"roa":"-58.82%","roe":"-175.68%","lyrEps":-7.349999,"volumeRatio":0.616118,"shares":6588099,"dividePrice":0,"high":1.53,"amplitude":0.061644,"preClose":1.46,"low":1.44,"week52Low":0.9661,"pbRate":"1.48","week52High":19.0289,"institutionHeld":0,"latestPrice":1.53,"committee":0.5625,"eps":-3.71934,"divideRate":0,"volume":37587,"delay":0,"ttmEps":-3.71934,"open":1.44,"prevYearClose":8.42,"prevWeekClose":1.46,"prevMonthClose":1.42,"prevQuarterClose":1.43,"fiveDayClose":1.48,"twentyDayClose":1.45,"sixtyDayClose":3.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MTVA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"MTVA","fiscalQuarterEnding":"2026/06","expectedEps":-0.85,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.9},{"market":"US","date":"2026-05-14","symbol":"MTVA","fiscalQuarterEnding":"2026/03","expectedEps":-0.76,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.79},{"date":"2026-03-26","symbol":"MTVA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":-2.06,"defaultRemindTime":1774512000000,"name":null,"time":"Pre-MKt","dateTimestamp":1774497600000,"actualEps":null},{"market":"US","date":"2025-12-05","symbol":"MTVA","defaultRemindTime":1764945000000,"type":"split","dateTimestamp":1764910800000,"forFactor":11,"toFactor":1,"ratio":11},{"market":"US","date":"2025-11-06","symbol":"MTVA","fiscalQuarterEnding":"2025/09","expectedEps":-0.26,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-0.14}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MTVA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MTVA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1735617600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MTVA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MTVA","date":"2026-08-21","current":-0.392543,"percent":0.377622,"low":-1.962939,"twenty":-1.052561,"median":-0.581699,"eighty":-0.462321,"high":-0.203888,"avg":-0.68903,"sd":0.331644,"marketCap":9486865},"quantilePoints":[{"date":"2024-12-06","current":-0.714557,"twenty":-0.800304,"median":-0.792227,"eighty":-0.751814,"marketCap":19816823},{"date":"2024-12-13","current":-0.716111,"twenty":-0.79347,"median":-0.728538,"eighty":-0.7158,"marketCap":19859903},{"date":"2024-12-20","current":-0.546792,"twenty":-0.767348,"median":-0.716111,"eighty":-0.685354,"marketCap":15164177},{"date":"2024-12-27","current":-0.562326,"twenty":-0.746234,"median":-0.70213,"eighty":-0.556112,"marketCap":15594978},{"date":"2025-01-03","current":-0.655529,"twenty":-0.730091,"median":-0.686597,"eighty":-0.553006,"marketCap":18179781},{"date":"2025-01-10","current":-0.661742,"twenty":-0.733198,"median":-0.686597,"eighty":-0.564811,"marketCap":18352101},{"date":"2025-01-17","current":-0.58718,"twenty":-0.720771,"median":-0.663296,"eighty":-0.577238,"marketCap":16284258},{"date":"2025-01-24","current":-0.602714,"twenty":-0.720771,"median":-0.647762,"eighty":-0.584073,"marketCap":16715059},{"date":"2025-01-31","current":-0.584073,"twenty":-0.717664,"median":-0.630675,"eighty":-0.584073,"marketCap":16198098},{"date":"2025-02-07","current":-0.562326,"twenty":-0.716111,"median":-0.615141,"eighty":-0.562326,"marketCap":15594978},{"date":"2025-02-14","current":-0.512617,"twenty":-0.714557,"median":-0.608927,"eighty":-0.546792,"marketCap":14216416},{"date":"2025-02-21","current":-0.509511,"twenty":-0.704615,"median":-0.602714,"eighty":-0.540578,"marketCap":14130256},{"date":"2025-02-28","current":-0.453589,"twenty":-0.699297,"median":-0.58718,"eighty":-0.518583,"marketCap":12579374},{"date":"2025-03-07","current":-0.487763,"twenty":-0.688995,"median":-0.584073,"eighty":-0.503297,"marketCap":13527135},{"date":"2025-03-14","current":-0.467569,"twenty":-0.681626,"median":-0.568539,"eighty":-0.495468,"marketCap":12967095},{"date":"2025-03-21","current":-0.48401,"twenty":-0.667956,"median":-0.562326,"eighty":-0.487763,"marketCap":13354815},{"date":"2025-03-28","current":-0.48933,"twenty":-0.662363,"median":-0.546792,"eighty":-0.487763,"marketCap":13501595},{"date":"2025-04-04","current":-0.47992,"twenty":-0.656772,"median":-0.540578,"eighty":-0.485083,"marketCap":13241949},{"date":"2025-04-11","current":-0.429732,"twenty":-0.643102,"median":-0.539025,"eighty":-0.482756,"marketCap":11857170},{"date":"2025-04-17","current":-0.23033,"twenty":-0.636267,"median":-0.537471,"eighty":-0.476844,"marketCap":6355270},{"date":"2025-04-25","current":-0.266622,"twenty":-0.631917,"median":-0.512617,"eighty":-0.463425,"marketCap":7356638},{"date":"2025-05-02","current":-0.239019,"twenty":-0.626947,"median":-0.506404,"eighty":-0.454331,"marketCap":6595010},{"date":"2025-05-09","current":-0.222708,"twenty":-0.618869,"median":-0.49874,"eighty":-0.452346,"marketCap":6144956},{"date":"2025-05-16","current":-0.238257,"twenty":-0.615141,"median":-0.497083,"eighty":-0.429105,"marketCap":5848960},{"date":"2025-05-23","current":-0.285534,"twenty":-0.611413,"median":-0.49458,"eighty":-0.263184,"marketCap":7009578},{"date":"2025-05-30","current":-0.543676,"twenty":-0.612655,"median":-0.49689,"eighty":-0.271352,"marketCap":13346706},{"date":"2025-06-06","current":-0.549972,"twenty":-0.608927,"median":-0.497673,"eighty":-0.281282,"marketCap":13501264},{"date":"2025-06-13","current":-0.597709,"twenty":-0.608927,"median":-0.503297,"eighty":-0.294785,"marketCap":14673160},{"date":"2025-06-20","current":-0.557862,"twenty":-0.607995,"median":-0.509511,"eighty":-0.332562,"marketCap":13694949},{"date":"2025-06-27","current":-0.542591,"twenty":-0.603956,"median":-0.515396,"eighty":-0.428478,"marketCap":13320078},{"date":"2025-07-03","current":-0.516978,"twenty":-0.602714,"median":-0.515103,"eighty":-0.429732,"marketCap":12691292},{"date":"2025-07-11","current":-0.572913,"twenty":-0.599701,"median":-0.516978,"eighty":-0.432869,"marketCap":14064436},{"date":"2025-07-18","current":-0.535431,"twenty":-0.597709,"median":-0.518414,"eighty":-0.439456,"marketCap":13144307},{"date":"2025-07-25","current":-0.587857,"twenty":-0.5965,"median":-0.521601,"eighty":-0.450482,"marketCap":14431313},{"date":"2025-08-01","current":-0.482926,"twenty":-0.587857,"median":-0.520838,"eighty":-0.453589,"marketCap":11855342},{"date":"2025-08-08","current":-0.674088,"twenty":-0.587857,"median":-0.518654,"eighty":-0.453589,"marketCap":12464564},{"date":"2025-08-15","current":-0.837521,"twenty":-0.602714,"median":-0.525504,"eighty":-0.453589,"marketCap":15486597},{"date":"2025-08-22","current":-0.836212,"twenty":-0.615141,"median":-0.534692,"eighty":-0.453589,"marketCap":15462399},{"date":"2025-08-29","current":-0.846681,"twenty":-0.624461,"median":-0.53558,"eighty":-0.454826,"marketCap":15655982},{"date":"2025-09-05","current":-0.898895,"twenty":-0.643102,"median":-0.537471,"eighty":-0.457336,"marketCap":16621475},{"date":"2025-09-12","current":-0.894708,"twenty":-0.675347,"median":-0.537746,"eighty":-0.459434,"marketCap":16544042},{"date":"2025-09-19","current":-1.200403,"twenty":-0.704615,"median":-0.540578,"eighty":-0.459802,"marketCap":22196650},{"date":"2025-09-26","current":-1.308626,"twenty":-0.720771,"median":-0.542033,"eighty":-0.464632,"marketCap":24197809},{"date":"2025-10-03","current":-1.285464,"twenty":-0.777314,"median":-0.543184,"eighty":-0.467223,"marketCap":23769507},{"date":"2025-10-10","current":-1.347885,"twenty":-0.814044,"median":-0.546792,"eighty":-0.468812,"marketCap":24923743},{"date":"2025-10-17","current":-1.360971,"twenty":-0.829721,"median":-0.548697,"eighty":-0.471608,"marketCap":25165721},{"date":"2025-10-24","current":-1.257721,"twenty":-0.836474,"median":-0.551486,"eighty":-0.475169,"marketCap":23256514},{"date":"2025-10-31","current":-1.275649,"twenty":-0.839353,"median":-0.556987,"eighty":-0.478202,"marketCap":23588024},{"date":"2025-11-07","current":-1.112332,"twenty":-0.856339,"median":-0.562326,"eighty":-0.479691,"marketCap":20568137},{"date":"2025-11-14","current":-0.985555,"twenty":-0.895545,"median":-0.562464,"eighty":-0.481224,"marketCap":15981760},{"date":"2025-11-21","current":-0.990035,"twenty":-0.925649,"median":-0.572913,"eighty":-0.482587,"marketCap":16054404},{"date":"2025-11-28","current":-1.16176,"twenty":-1.03994,"median":-0.573323,"eighty":-0.482894,"marketCap":18839105},{"date":"2025-12-05","current":-0.993021,"twenty":-1.048481,"median":-0.575956,"eighty":-0.483005,"marketCap":16102829},{"date":"2025-12-12","current":-1.162032,"twenty":-1.114901,"median":-0.581053,"eighty":-0.483057,"marketCap":18843504},{"date":"2025-12-19","current":-1.126736,"twenty":-1.121412,"median":-0.584073,"eighty":-0.483629,"marketCap":18271155},{"date":"2025-12-26","current":-1.324933,"twenty":-1.135751,"median":-0.58567,"eighty":-0.484268,"marketCap":21485117},{"date":"2026-01-02","current":-1.143026,"twenty":-1.158344,"median":-0.587519,"eighty":-0.484763,"marketCap":18535316},{"date":"2026-01-09","current":-1.138004,"twenty":-1.161978,"median":-0.597709,"eighty":-0.485344,"marketCap":18453866},{"date":"2026-01-16","current":-0.447979,"twenty":-1.16176,"median":-0.601208,"eighty":-0.485344,"marketCap":7264435},{"date":"2026-01-23","current":-0.551981,"twenty":-1.16176,"median":-0.598705,"eighty":-0.485958,"marketCap":8950917},{"date":"2026-01-30","current":-0.466908,"twenty":-1.144681,"median":-0.593528,"eighty":-0.48519,"marketCap":7571385},{"date":"2026-02-06","current":-0.342268,"twenty":-1.143026,"median":-0.58718,"eighty":-0.483057,"marketCap":5550210},{"date":"2026-02-13","current":-0.328419,"twenty":-1.140855,"median":-0.584073,"eighty":-0.480757,"marketCap":5325635},{"date":"2026-02-20","current":-0.308634,"twenty":-1.138574,"median":-0.583444,"eighty":-0.475169,"marketCap":5004813},{"date":"2026-02-27","current":-0.31457,"twenty":-1.130076,"median":-0.57751,"eighty":-0.466694,"marketCap":5101060},{"date":"2026-03-06","current":-0.31457,"twenty":-1.127008,"median":-0.573733,"eighty":-0.459434,"marketCap":5101060},{"date":"2026-03-13","current":-0.318526,"twenty":-1.122978,"median":-0.572913,"eighty":-0.453589,"marketCap":5165224},{"date":"2026-03-20","current":-0.292807,"twenty":-1.121203,"median":-0.56645,"eighty":-0.449981,"marketCap":4748156},{"date":"2026-03-27","current":-0.359359,"twenty":-1.119202,"median":-0.562326,"eighty":-0.429418,"marketCap":4661961},{"date":"2026-04-02","current":-0.490532,"twenty":-1.117842,"median":-0.56111,"eighty":-0.431614,"marketCap":6363670},{"date":"2026-04-10","current":-0.466986,"twenty":-1.114293,"median":-0.557862,"eighty":-0.436821,"marketCap":6058213},{"date":"2026-04-17","current":-0.549396,"twenty":-1.111355,"median":-0.557553,"eighty":-0.44457,"marketCap":7127310},{"date":"2026-04-24","current":-0.605091,"twenty":-1.10949,"median":-0.558572,"eighty":-0.449481,"marketCap":7849842},{"date":"2026-05-01","current":-0.573244,"twenty":-1.107704,"median":-0.562326,"eighty":-0.452346,"marketCap":7436692},{"date":"2026-05-08","current":-0.529454,"twenty":-1.10583,"median":-0.562326,"eighty":-0.453589,"marketCap":6868612},{"date":"2026-05-15","current":-0.473722,"twenty":-1.101758,"median":-0.559233,"eighty":-0.449481,"marketCap":6145600},{"date":"2026-05-22","current":-1.129276,"twenty":-1.10583,"median":-0.559894,"eighty":-0.44457,"marketCap":14821741},{"date":"2026-05-29","current":-1.219775,"twenty":-1.111681,"median":-0.562326,"eighty":-0.44898,"marketCap":16009547},{"date":"2026-06-05","current":-0.964016,"twenty":-1.111681,"median":-0.563942,"eighty":-0.451725,"marketCap":12652706},{"date":"2026-06-12","current":-0.790886,"twenty":-1.109895,"median":-0.569786,"eighty":-0.453589,"marketCap":10380383},{"date":"2026-06-18","current":-0.672844,"twenty":-1.108355,"median":-0.572913,"eighty":-0.453589,"marketCap":8831072},{"date":"2026-06-26","current":-0.602018,"twenty":-1.106645,"median":-0.573284,"eighty":-0.453589,"marketCap":7901486},{"date":"2026-07-02","current":-0.57054,"twenty":-1.105016,"median":-0.573244,"eighty":-0.453589,"marketCap":7488336},{"date":"2026-07-10","current":-0.680713,"twenty":-1.099586,"median":-0.573733,"eighty":-0.454826,"marketCap":8934360},{"date":"2026-07-17","current":-0.708256,"twenty":-1.074189,"median":-0.57751,"eighty":-0.457016,"marketCap":9295866},{"date":"2026-07-24","current":-0.594148,"twenty":-1.066319,"median":-0.582344,"eighty":-0.457963,"marketCap":7798198},{"date":"2026-07-31","current":-0.566605,"twenty":-1.0655,"median":-0.57786,"eighty":-0.458903,"marketCap":7436692},{"date":"2026-08-07","current":-0.57054,"twenty":-1.056933,"median":-0.57751,"eighty":-0.459669,"marketCap":7488336},{"date":"2026-08-14","current":-0.665833,"twenty":-1.054581,"median":-0.577159,"eighty":-0.459802,"marketCap":9618627},{"date":"2026-08-21","current":-0.656712,"twenty":-1.052561,"median":-0.581699,"eighty":-0.462321,"marketCap":9486865}],"updateTime":1787574558774},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MTVA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2638150071","title":"MetaVia says Phase 1 trial shows DA-1726 cuts mean body weight up to 9.1% at 48 mg dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2638150071","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638150071?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:33","pubTimestamp":1779885207,"startTime":"0","endTime":"0","summary":"MetaVia presented higher-dose Phase 1 results for obesity drug candidate DA-1726 at EASL 2026 on May 27.The study showed meaningful, continuing weight loss with no sign of an early plateau during follow-up.Safety profile looked manageable, with mostly mild-to-moderate gastrointestinal side effects and no treatment-related dropouts reported.Exploratory liver scans suggested early improvements consistent with potential use in obesity-related liver disease, including MASH.Ongoing Phase 1 titration studies are testing longer treatment and higher-dose strategies to support next-stage development.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL185sW6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638002545","title":"Metavia Presents Higher-Dose Phase 1 Results for Da-1726 at Easl Congress 2026, Supporting Potential in Obesity and Mash","url":"https://stock-news.laohu8.com/highlight/detail?id=2638002545","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638002545?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:31","pubTimestamp":1779885061,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nTUA3KYGH8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637631645","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2637631645","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637631645?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:18","pubTimestamp":1779448694,"startTime":"0","endTime":"0","summary":"PicoCELA  shares were up 172% in Friday premarket activity, extending Thursday's 60% rally.Leifras  stock was 113% higher after the company agreed to acquire Tokai Sports.Akari Therapeutics  shares were up 64% after the company reported positive preclinical data for its AKTX-101 investigational drug candidate.MetaVia  stock was 40% higher following a muted session.HCW Biologics  shares were up 25% after the company priced a private securities offering.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PCLA","BK4007","LFS","BK4020","BK7093","BK4539","AKTS","BK4204","MTVA","BK4139","BK4148","HCWB","LFS.AU","AKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637684352","title":"Why MetaVia Stock Is Falling On Thursday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2637684352","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637684352?lang=en_us&edition=fundamental","pubTime":"2026-05-22 02:30","pubTimestamp":1779388200,"startTime":"0","endTime":"0","summary":"MetaVia Inc. (NASDAQ: MTVA) shares drop over 10% on Thursday due to profit-taking despite announcing peer-reviewed data supporting its anti-fibrotic MASH drug candidate.","market":"us","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=260,dpr=2,format=auto,quality=85/files/images/story/2026/05/21/Financial-Market-Crash-Concept-With-Red-.jpeg","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=260,dpr=2,format=auto,quality=85/files/images/story/2026/05/21/Financial-Market-Crash-Concept-With-Red-.jpeg"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/05/52728981/why-metavia-stock-is-falling-on-thursday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/05/52728981/why-metavia-stock-is-falling-on-thursday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636844503","title":"MetaVia cites preclinical study showing vanoglipel reduces liver fibrosis in MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2636844503","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636844503?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:02","pubTimestamp":1779278560,"startTime":"0","endTime":"0","summary":"MetaVia highlighted a newly published peer-reviewed preclinical study supporting an anti-fibrotic effect for its GPR119 agonist vanoglipel in metabolic liver disease.Results were already presented via the journal publication, with findings indicating reduced liver scarring signals in laboratory models.The readout adds mechanistic support to a previously completed Phase 2a study in presumed MASH, which showed improvements in liver injury and fibrosis markers versus placebo.The company positioned the data as strengthening the case for vanoglipel as a potential standalone therapy or a combination option in MASH with fibrosis.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL2qHcCS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636865778","title":"Sector Update: Healthcare Stocks Rise Tuesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2636865778","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636865778?lang=en_us&edition=fundamental","pubTime":"2026-05-20 02:02","pubTimestamp":1779213753,"startTime":"0","endTime":"0","summary":"Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) gaining 1.2%.The iShares Biotechnology ETF (IBB) incre","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0689472784.USD","BK4550","XBI","LU2023250843.SGD","IBB","LU0266013472.USD","LU2237443978.SGD","MTVA","IE00BWXC8680.SGD","IE00B4R5TH58.HKD","LU2362541513.USD","LU0234572021.USD","LU0640476718.USD","JPMO","LU2054465674.USD","TLSA","LABU","LU0353189763.USD","BK4516","LU1670627923.USD","JPO","LU1244550494.USD","LU0203347892.USD","IE00BJTD4N35.SGD","IE0034235295.USD","XLV","BK4139","LU2265009873.SGD","IE00B1XK9C88.USD","LU1718418525.SGD","LU0208291251.USD","LU2505996509.AUD","HCSG","IE0009355771.USD","JPX","LU0203345920.USD","LU1791710582.SGD","LU1989772840.SGD","LU0149725797.USD","RLAY","BSX","LU0106261372.USD","LU2491049909.HKD","BK4581","LU2552382058.USD","LU1057294990.SGD","LU2746668461.USD","BSX.AU","LU2746668974.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636585391","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2636585391","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636585391?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:26","pubTimestamp":1779190011,"startTime":"0","endTime":"0","summary":"Amesite  shares were up 212% in Tuesday premarket trading after the company said it secured a new enterprise customer for its NurseMagic platform.Rubico  shares were 117% higher, recovering from a 6.5% decline on MondayMeiwu Technology  stock was 88% higher, recovering from Monday's 22% decline.MetaVia  shares were up 75% after the company said three late-breaking abstracts highlighting its cardiometabolic assets were accepted for poster presentations.Hub Cyber Security  stock was 18% higher, rebounding from Monday's 6.7% decline.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4122","BK4139","AMST","HUBC","RUBI","BK4134","BK4204","BK4144","BK4113","WNW","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636407130","title":"MetaVia Price Target Maintained With a $20.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2636407130","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636407130?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:59","pubTimestamp":1779112740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MTVA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 18, 2026 09:59 ET (13:59 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636607589","title":"MetaVia presents Phase 1 higher-dose DA-1726 obesity data at ADA 2026 sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=2636607589","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636607589?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:32","pubTimestamp":1779107524,"startTime":"0","endTime":"0","summary":"MetaVia flagged new Phase 1 higher-dose cohort results for its obesity drug candidate DA-1726, with data slated for presentation at the American Diabetes Association’s 2026 Scientific Sessions on June 7.The readout is positioned to clarify whether the dual GLP-1/glucagon program can support higher dosing with improved tolerability, a key step toward differentiation in the obesity market.Two additional late-breaking posters will present preclinical work on vanoglipel, pointing to potential synergy in combinations aimed at MASH and Type 2 diabetes.The conference disclosures set up a near-term catalyst cycle for the pipeline, with the company also targeting a separate update from an ongoing 16-week Phase 1 titration study in the fourth quarter.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDLbsMkt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635296907","title":"MetaVia Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635296907","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635296907?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:01","pubTimestamp":1778792467,"startTime":"0","endTime":"0","summary":"MetaVia Inc reports results for the quarter ended March 31 - Earnings SummaryMetaVia Inc MTVA.OQ reported a quarterly adjusted loss of 42 cents per share for the quarter ended March 31, higher than th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R2JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635267047","title":"MetaVia Q1 EPS $(0.79) Misses $(0.74) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635267047","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635267047?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:48","pubTimestamp":1778791696,"startTime":"0","endTime":"0","summary":"MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.79) per share which missed the analyst consensus estimate of $(0.74) by 6.76 percent. This is a 80.05 percent increase over losses of $(3.96) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52582906/metavia-q1-eps-0-79-misses-0-74-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"MetaVia Q1 EPS $(0.79) Misses $(0.74) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635725475","title":"MetaVia publishes investor presentation on obesity, MASH drug pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2635725475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635725475?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:25","pubTimestamp":1778790317,"startTime":"0","endTime":"0","summary":"MetaVia investor deck highlighted lead obesity candidate DA-1726, a once-weekly GLP-1R/GCGR dual agonist, with Phase 1 multi-ascending dose data showing 9.1% weight loss at 48 mg by Day 54 with no titration.Same dataset showed 3.8-inch waist reduction, 0.22 HbA1c decline, 23.7% drop in liver stiffness , with mostly mild-to-moderate side effects.Program plan targets tolerability optimization with stepwise titration up to 64 mg, with Phase 1 Part 3 readout expected in Q4 2026.MASH asset vanoglipel , an oral GPR119 agonist, posted Phase 2a primary endpoint success in presumed MASH, with ALT down 22.8 U/L at Week 16, with significant HbA1c reductions at 100 mg versus placebo.Cash and cash equivalents were USD 13.7 million as of March 31, 2026, with no debt; capitalization table listed 5,164,370 common shares outstanding, 15,410,509 fully diluted.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDLTjSd1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635723052","title":"MetaVia Q1 net loss widens 4.1% to $3.82 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635723052","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635723052?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:14","pubTimestamp":1778789655,"startTime":"0","endTime":"0","summary":"Metavia posted a Q1 net loss of USD 3.82 million, widening from prior-year period, while loss per share narrowed to USD 0.79.Operating loss widened to USD 4.03 million as total operating expenses rose 3.6% to USD 4.03 million.Research and development spending fell 9.7% to USD 2.1 million, while general and administrative costs climbed 23.4% to USD 1.92 million.Cash and cash equivalents totaled USD 13.7 million at March 31, 2026; net cash used in operating activities was USD 4.26 million.DA-1726 Phase 1 Part 3a and 3b studies started in April 2026 with data readout planned for Q4 2026, while vanoglipel Phase 2a clinical study report is expected in first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDLbbGJgK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635272380","title":"Metavia Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635272380","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635272380?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789103,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA51XJYM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635723138","title":"Press Release: MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635723138","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635723138?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789100,"startTime":"0","endTime":"0","summary":"48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit. Key Milestone Achieved with Dosing of the First Patient in Phase 1 Part 3 16-Week Titration Study Evaluating 48 mg  and 64 mg  Regimens; Data Expected in Fourth Quarter 2026. CAMBRIDGE, Mass., May 14, 2026 /PRNewswire/ -- MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate strategic update.-- May 2026: Announced the presentation of additional data from the 48 mg. Phase 1 trial of DA-1726 at the EASL Congress 2026 in a poster entitled,an Oxyntomodulin Analogue, in a Higher-Dose Phase 1 Cohort with. -- April 2026: Dosed the first patient in Part 3 of the Phase 1 clinical. trial evaluating DA-1726 in obese, otherwise healthy adults, consisting. of two 16-week titration cohorts designed to ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4202","OXM","BK4232","MTVA","BK4139","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634890642","title":"MetaVia highlights higher-dose Phase 1 DA-1726 data in EASL late-breaking poster","url":"https://stock-news.laohu8.com/highlight/detail?id=2634890642","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634890642?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:33","pubTimestamp":1778502804,"startTime":"0","endTime":"0","summary":"MetaVia flagged new Phase 1 higher-dose cohort data for obesity drug candidate DA-1726, a dual GLP-1/glucagon agonist, in a late-breaking poster accepted for EASL Congress 2026.Results have not yet been presented; poster is scheduled for May 27, 2026 in Barcelona.Readout is set to focus on safety, tolerability, drug exposure, pharmacodynamic activity, with an exploratory noninvasive liver assessment, positioning the program for dose optimization and potential differentiation in obesity.Company is running a 16-week Phase 1 Part 3 titration study to test higher dose levels and improve tolerability, with additional data expected in Q4 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL8qTRSy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634965498","title":"MetaVia Inc  expected to post a loss of 74 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634965498","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634965498?lang=en_us&edition=fundamental","pubTime":"2026-05-09 06:57","pubTimestamp":1778281026,"startTime":"0","endTime":"0","summary":"MetaVia Inc  expected to post a loss of74cents a share - Earnings Preview MetaVia Inc MTVA.OQ MTVA.O is expected to  show no change in quarterly revenue when it reports  results on May 12 (estimated) ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L2VB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627237901","title":"MetaVia announces annual shareholder meeting webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237901","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237901?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:02","pubTimestamp":1776283374,"startTime":"0","endTime":"0","summary":"MetaVia schedules virtual annual stockholder meeting for June 8, 2026.Vote set on election of two Class I directors to three-year terms ending at 2029 annual meeting.Ballot includes ratification of BDO USA as independent registered public accounting firm for fiscal 2026.Stockholders to consider reverse stock split within 1-for-5 to 1-for-22 range.Additional items include increasing 2022 Equity Incentive Plan share pool by 200,000 shares, with possible adjournment to seek more votes on reverse split or equity plan amendment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL7bTQ3f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626190668","title":"MetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726","url":"https://stock-news.laohu8.com/highlight/detail?id=2626190668","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626190668?lang=en_us&edition=fundamental","pubTime":"2026-04-10 20:36","pubTimestamp":1775824584,"startTime":"0","endTime":"0","summary":"MetaVia (MTVA) announced that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodul...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/metavia-says-first-patient-dosed-in-part-3-of-phase-1-trial-of-da-1726-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/metavia-says-first-patient-dosed-in-part-3-of-phase-1-trial-of-da-1726-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626903771","title":"MetaVia doses first patient in higher-dose Phase 1 trial of obesity drug DA-1726","url":"https://stock-news.laohu8.com/highlight/detail?id=2626903771","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626903771?lang=en_us&edition=fundamental","pubTime":"2026-04-10 20:32","pubTimestamp":1775824337,"startTime":"0","endTime":"0","summary":"MetaVia dosed first patient in higher-dose Phase 1 study Part 3 for DA-1726, its dual GLP-1 and glucagon agonist for obesity.Program targets faster escalation to higher doses to improve tolerability, positioning drug for a more streamlined dosing path versus marketed options.Earlier Phase 1 data were already presented, showing meaningful weight loss and broader metabolic improvements without detailing technical measures.New results will be presented in fourth quarter 2026.Study plans to enroll 40 obese, otherwise healthy adults across two 16-week titration cohorts.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL42mxM8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":61,"code":"91000000","status":"200"}]}}